OA
GILD icon

Opes Advisors’s Gilead Sciences GILD Stock Holding History

Opes Advisors’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-97,789
Closed -$7.92M – 46
2017
Q3 		$7.92M Hold
97,789
– – 5.07% 8
2017
Q2 		$7.33M Sell
97,789
-19
-0% -$1.26K 4.54% 8
2017
Q1 		$6.64M Buy
+97,808
New +$6.88M 4.69% 8

Other funds holding GILD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Parnassus Investments
Parnassus Investments San Francisco, California $37.4B AUM 35.42% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Opes Advisors's GILD Position: Q4 2017 in Review

Opes Advisors sold out of Gilead Sciences (GILD) in Q4 2017, closing a stake of 97,789 shares — an estimated $7.92M sold.

Opes Advisors first reported a position in GILD in Q1 2017 and held it in 3 quarters. The position peaked at $7.92M in Q3 2017. 1,575 funds tracked by Wall St. Rank hold GILD as of Q4 2017.

  • Opes Advisors reported no remaining Gilead Sciences position as of Q4 2017 after selling out during the quarter.
  • Opes Advisors sold 97,789 Gilead Sciences shares in Q4 2017, an estimated $7.92M.
  • Opes Advisors first reported a position in Gilead Sciences in Q1 2017 and held it in 3 quarters.
  • Opes Advisors's Gilead Sciences position peaked at $7.92M in Q3 2017.
  • 1,575 funds tracked by Wall St. Rank held Gilead Sciences as of Q4 2017.

Based on Opes Advisors's 13F filing for Q4 2017, filed 9 Feb 2018.